{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:58:23Z","timestamp":1793213903725,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009550","name":"Hasselt University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"FWO","doi-asserted-by":"publisher","award":["1192221N"],"award-info":[{"award-number":["1192221N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006401","name":"Charcot Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.autrev.2024.103532","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T10:39:17Z","timestamp":1711103957000},"page":"103532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases"],"prefix":"10.1016","volume":"23","author":[{"given":"Mirre","family":"De Bondt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Renders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Struyf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Hellings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2024.103532_bb0005","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1126\/science.8332901","article-title":"Mutation of unique region of Bruton\u2019s tyrosine kinase in immunodeficient XID mice","volume":"261","author":"Rawlings","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.autrev.2024.103532_bib551","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2024.103532_bb0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12098-015-2024-8","article-title":"X-linked Agammaglobulinemia","volume":"83","author":"Suri","year":"2016","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.autrev.2024.103532_bb0015","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1093\/emboj\/17.7.1973","article-title":"Btk\/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation","volume":"17","author":"Fluckiger","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.autrev.2024.103532_bb0020","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1084\/jem.192.11.1611","article-title":"Severe B cell deficiency in mice lacking the Tec kinase family members Tec and Btk","volume":"192","author":"Ellmeier","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2024.103532_bb0025","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.4049\/jimmunol.1601285","article-title":"Distinct and overlapping functions of TEC kinase and BTK in B cell receptor signaling","volume":"198","author":"de Bruijn","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2024.103532_bib552","volume":"20","author":"Estupi\u00f1an Velasquez","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.autrev.2024.103532_bb0030","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton\u2019s tyrosine kinase in the immune system and disease","volume":"164","author":"McDonald","year":"2021","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2024.103532_bb0035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton\u2019s tyrosine kinase and phospholipase C\u03b32 mediate chemokine-controlled B cell migration and homing","volume":"26","author":"De Gorter","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2024.103532_bb0040","doi-asserted-by":"crossref","first-page":"21537","DOI":"10.1074\/jbc.M201903200","article-title":"Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. Implication of phosphatidynositol 3-kinases","volume":"277","author":"Lachance","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2024.103532_bb0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.autrev.2024.103532_bb0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc\u03b3 receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2024.103532_bb0055","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1242\/jcs.071043","article-title":"Btk-dependent Rac activation and actin rearrangement following Fc\u03b5RI aggregation promotes enhanced chemotactic responses of mast cells","volume":"123","author":"Kuehn","year":"2010","journal-title":"J Cell Sci"},{"key":"10.1016\/j.autrev.2024.103532_bb0060","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4049\/jimmunol.182.1.329","article-title":"Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells","volume":"182","author":"Sharma","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2024.103532_bb0065","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/sj.onc.1206425","article-title":"BCR targets cyclin D2 via Btk and the p85\u03b1 subunit of PI3-K to induce cell cycle progression in primary mouse B cells","volume":"22","author":"Glassford","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.autrev.2024.103532_bb0070","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1084\/jem.187.7.1081","article-title":"Transgene expression of bcl-xL permits anti-immunoglobulin (Ig)\u2013induced proliferation in xid B cells","volume":"187","author":"Solvason","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2024.103532_bb0075","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1038\/ncomms6456","article-title":"The immunoglobulin tail tyrosine motif upgrades memory-type BCRs by incorporating a Grb2-Btk signalling module","volume":"5","author":"Engels","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2024.103532_bb0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fimmu.2019.00095","article-title":"Toll-like receptor signaling drives Btk-mediated autoimmune disease","volume":"10","author":"Rip","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103532_bb0085","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1111\/bph.15778","article-title":"Bruton\u2019s TK regulates myeloid cell recruitment during acute inflammation","volume":"179","author":"Purvis","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2024.103532_bb0090","doi-asserted-by":"crossref","first-page":"6836","DOI":"10.1038\/s41598-017-06342-5","article-title":"Transcriptome profiling of monocytes from XLA patients revealed the innate immune function dysregulation due to the BTK gene expression deficiency","volume":"7","author":"Mirsafian","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2024.103532_bb0095","first-page":"181","article-title":"Defective fc-, CR1- and CR3-mediated monocyte phagocytosis and chemotaxis in common variable immunodeficiency and X-linked agammaglobulinemia patients","volume":"13","author":"Amoras","year":"2003","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.autrev.2024.103532_bb0100","doi-asserted-by":"crossref","first-page":"7203","DOI":"10.4049\/jimmunol.177.10.7203","article-title":"Bruton\u2019s tyrosine kinase is required for TLR-induced IL-10 production","volume":"177","author":"Schmidt","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2024.103532_bb0105","doi-asserted-by":"crossref","first-page":"8048","DOI":"10.4049\/jimmunol.180.12.8048","article-title":"Essential roles for the Tec family kinases Tec and Btk in M-CSF receptor signaling pathways that regulate macrophage survival","volume":"180","author":"Melcher","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2024.103532_bb0110","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1074\/jbc.M110.165613","article-title":"Absence of Tec family kinases Interleukin-2 inducible T cell kinase (Itk) and Bruton\u2019s tyrosine kinase (Btk) severely impairs Fc\u03f5RI-dependent mast cell responses","volume":"286","author":"Iyer","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2024.103532_bb0115","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/all.13166","article-title":"BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils","volume":"72","author":"Smiljkovic","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.autrev.2024.103532_bb0120","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.md.0000229482.27398.ad","article-title":"X-linked agammaglobulinemia: report on a United States registry of 201 patients","volume":"85","author":"Winkelstein","year":"2006","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2024.103532_bb0125","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2010-04-281170","article-title":"Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia","volume":"117","author":"Fiedler","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103532_bb0130","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood-2009-11-254185","article-title":"Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) gamma2 and PI3Kgamma pathways","volume":"115","author":"Mueller","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103532_bb0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.immuni.2015.11.011","article-title":"The neutrophil Btk signalosome regulates integrin activation during sterile inflammation","volume":"44","author":"Volmering","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2024.103532_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106233","article-title":"Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment","volume":"87","author":"Prezzo","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.autrev.2024.103532_bb0145","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood-2004-01-0207","article-title":"Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses","volume":"104","author":"Mangla","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103532_bb0150","doi-asserted-by":"crossref","first-page":"7360","DOI":"10.1038\/ncomms8360","article-title":"Bruton\u2019s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury","volume":"6","author":"Ito","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2024.103532_bb0155","article-title":"Bruton\u2019s tyrosine kinase and protein kinase C \u03bc are required for TLR7\/9-induced IKK\u03b1 and IRF-1 activation and interferon-\u03b2 production in conventional dendritic cells","volume":"9","author":"Li","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2024.103532_bb0160","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/eji.201344030","article-title":"Bruton\u2019s tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells","volume":"44","author":"Wang","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2024.103532_bb0165","doi-asserted-by":"crossref","first-page":"11526","DOI":"10.1074\/jbc.M708935200","article-title":"The Tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation","volume":"283","author":"Lee","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2024.103532_bb0170","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cell.2007.12.037","article-title":"Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals","volume":"132","author":"Shinohara","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2024.103532_bb0175","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2011-12-397919","article-title":"Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice","volume":"119","author":"Kil","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103532_bb0180","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/art.40059","article-title":"Enhanced Bruton\u2019s tyrosine kinase activity in peripheral blood B lymphocytes from patients with autoimmune disease","volume":"69","author":"Corneth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103532_bb0185","article-title":"Bruton tyrosine kinase inhibition in multiple sclerosis","author":"Jayagopal","year":"2022","journal-title":"Pract Neurol"},{"key":"10.1016\/j.autrev.2024.103532_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113329","article-title":"Emerging small-molecule inhibitors of the Bruton\u2019s tyrosine kinase (BTK): current development","volume":"217","author":"Liu","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.autrev.2024.103532_bb0195","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1515\/BC.2004.045","article-title":"The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity","volume":"385","author":"Van Den Akker","year":"2004","journal-title":"Biol Chem"},{"key":"10.1016\/j.autrev.2024.103532_bb0200","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1177\/13524585221091060","article-title":"All Bruton\u2019s tyrosine kinase inhibitors have similar efficacy and risks: No","volume":"28","author":"Rotstein","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2024.103532_bb0205","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11910-022-01229-z","article-title":"Bruton\u2019s tyrosine kinase inhibition in multiple sclerosis","volume":"22","author":"Schneider","year":"2022","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.autrev.2024.103532_bb0210","doi-asserted-by":"crossref","first-page":"9269","DOI":"10.3390\/ijms21239269","article-title":"Discovery of a novel class of covalent dual inhibitors targeting the protein kinases BMX and BTK","volume":"21","author":"Forster","year":"2020","journal-title":"IJMS"},{"key":"10.1016\/j.autrev.2024.103532_bb0215","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (Remibrutinib), a potent and highly selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.autrev.2024.103532_bb0220","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1212\/WNL.0000000000203897","article-title":"Comparative CNS pharmacology of Tolebrutinib versus other BTK inhibitor candidates for treating MS (S46.007)","volume":"100","author":"Turner","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2024.103532_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114009","article-title":"Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib","volume":"229","author":"Ran","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.autrev.2024.103532_bb0235","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kr\u00e4mer","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2024.103532_bb0240","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/BPL-200100","article-title":"Bruton\u2019s tyrosine kinase inhibition promotes myelin repair","volume":"5","author":"Martin","year":"2020","journal-title":"Brain Plast"},{"key":"10.1016\/j.autrev.2024.103532_bb0245","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1093\/brain\/awab231","article-title":"MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response","volume":"144","author":"Pellerin","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2024.103532_bb0250","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160909","article-title":"Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib","volume":"7","author":"Rijvers","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2024.103532_bb0255","first-page":"989","article-title":"PRN2246, a potent and selective blood brain barrier penetrating BTK inhibitor, exhibits efficacy in central nervous system immunity","author":"Francesco","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1016\/j.autrev.2024.103532_bb0260","first-page":"270","article-title":"Decoding bruton\u2019s tyrosine kinase signalling in neuroinfammation","volume":"26","author":"Gruber","year":"2020","journal-title":"ECTRIMS"},{"key":"10.1016\/j.autrev.2024.103532_bb0265","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","article-title":"Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Reich","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2024.103532_bb0270","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.2147\/DDDT.S348129","article-title":"Current perspectives: evidence to date on BTK inhibitors in the management of multiple sclerosis","volume":"16","author":"Carnero Contentti","year":"2022","journal-title":"DDDT"},{"key":"10.1016\/j.autrev.2024.103532_bb0275","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-020-02204-z","article-title":"Inhibition of Bruton\u2019s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease","volume":"140","author":"Torke","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.autrev.2024.103532_bb0280","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1111\/cts.13108","article-title":"Evobrutinib, a covalent Bruton\u2019s tyrosine kinase inhibitor: mass balance, elimination route, and metabolism in healthy participants","volume":"14","author":"Scheible","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.autrev.2024.103532_bb0285","article-title":"Merck evobrutinib fails in trials: a devastating outcome for MS","author":"Darma","year":"2023","journal-title":"Clin Trial Vang"},{"key":"10.1016\/j.autrev.2024.103532_bb0290","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-controlled trial of an Oral BTK inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103532_bb0295","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: a potent, selective, and noncovalent Bruton\u2019s tyrosine kinase inhibitor in early clinical development","volume":"61","author":"Crawford","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.autrev.2024.103532_bb0300","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12974-023-02877-9","article-title":"Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis","volume":"20","author":"Nuesslein-Hildesheim","year":"2023","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2024.103532_bb0305","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/rheumatology\/keu532","article-title":"Amplification of IL-21 signalling pathway through Bruton\u2019s tyrosine kinase in human B cell activation","volume":"54","author":"Wang","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2024.103532_bb0310","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar2478","article-title":"Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis","volume":"10","author":"Zhao","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2024.103532_bb0315","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.1021\/acs.jmedchem.9b00794","article-title":"Discovery of Evobrutinib: an Oral, potent, and highly selective, covalent Bruton\u2019s tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases","volume":"62","author":"Caldwell","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.autrev.2024.103532_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jnnp-2022-328799","article-title":"Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis","volume":"94","author":"Montalban","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2024.103532_bb0325","series-title":"Evobrutinib fails to improve response rate in refractory RA patients","author":"Piper","year":"2020"},{"key":"10.1016\/j.autrev.2024.103532_bb0330","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/ITT.S288550","article-title":"Bruton\u2019s tyrosine kinase inhibition for the treatment of rheumatoid arthritis","volume":"10","author":"Arneson","year":"2021","journal-title":"Immuntargets Ther"},{"key":"10.1016\/j.autrev.2024.103532_bb0335","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, Phase II Trial","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103532_bb0340","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/bcp.14290","article-title":"Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton\u2019s tyrosine kinase: randomised phase I, placebo-controlled trial in healthy participants","volume":"86","author":"Catlett","year":"2020","journal-title":"Brit J Clinical Pharma"},{"key":"10.1016\/j.autrev.2024.103532_bb0345","article-title":"Bruton\u2019s tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption","volume":"10","author":"Ariza","year":"2019","journal-title":"Bone Rep"},{"key":"10.1016\/j.autrev.2024.103532_bb0350","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1172\/JCI110651","article-title":"Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA","volume":"70","author":"Steinberg","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2024.103532_bb0355","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10067-017-3717-3","article-title":"Increased expression of Bruton\u2019s tyrosine kinase in peripheral blood is associated with lupus nephritis","volume":"37","author":"Kong","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2024.103532_bb0360","doi-asserted-by":"crossref","first-page":"26164","DOI":"10.1038\/srep26164","article-title":"Therapeutic blockade of immune complex-mediated glomerulonephritis by highly selective inhibition of Bruton\u2019s tyrosine kinase","volume":"6","author":"Chalmers","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2024.103532_bb0365","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.4049\/jimmunol.1800583","article-title":"Efficacy and Pharmacodynamic modeling of the BTK inhibitor Evobrutinib in autoimmune disease models","volume":"202","author":"Haselmayer","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2024.103532_bb0370","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90111","article-title":"Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell\u2013associated damage in IFN\u03b1-driven lupus nephritis","volume":"2","author":"Katewa","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2024.103532_bb0375","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/acr2.11511","article-title":"Efficacy and safety of the bruton\u2019s tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind placebo-controlled dose-ranging trial","volume":"5","author":"Wallace","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2024.103532_bb0380","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, safety, and Pharmacodynamic effects of the Bruton\u2019s tyrosine kinase inhibitor Fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103532_bb0385","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1021\/acs.jmedchem.9b00167","article-title":"Discovery of Branebrutinib (BMS-986195): a strategy for identifying a highly potent and selective covalent inhibitor providing rapid in vivo inactivation of Bruton\u2019s tyrosine kinase (BTK)","volume":"62","author":"Watterson","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.autrev.2024.103532_bb0390","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/14397595.2018.1484269","article-title":"ABBV-105, a selective and irreversible inhibitor of Bruton\u2019s tyrosine kinase, is efficacious in multiple preclinical models of inflammation","volume":"29","author":"Goess","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2024.103532_bb0395","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2022-eular.5086a","article-title":"LB0005 orelabrutinib, an irreversible inhibitor of bruton\u2019s tyrosine kinase (BTK), for the treatment of systemic lupus erythematosus (SLE): results of a randomized, double-blind, placebo-controlled, phase IB\/IIA dose-finding study","volume":"81","author":"Li","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103532_bb0400","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0961203318801673","article-title":"Primary Sj\u00f6gren\u2019s syndrome","volume":"27","author":"Bowman","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103532_bb0405","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/art.40215","article-title":"Brief report: defective early B cell tolerance checkpoints in Sj\u00f6gren\u2019s syndrome patients","volume":"69","author":"Glauzy","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103532_bb0410","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/art.42550","article-title":"Association between Bruton\u2019s tyrosine kinase gene overexpression and risk of lymphoma in primary Sj\u00f6gren\u2019s syndrome","volume":"75","author":"Duret","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103532_bb0415","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/cts.13005","article-title":"Remibrutinib (LOU064): a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial","volume":"14","author":"Kaul","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.autrev.2024.103532_bb0420","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren\u2019s syndrome: a randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2024.103532_bb0425","article-title":"Preliminary results of a double-blind randomised trial of rituximab anti-B-cell therapy in patients with primary Sjogrens syndrome","volume":"67","author":"Bowman","year":"2015","journal-title":"ACR\/ARHP"},{"key":"10.1016\/j.autrev.2024.103532_bb0430","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1152\/physrev.00012.2018","article-title":"The Neutrophil\u2019s role during health and disease","volume":"99","author":"Liew","year":"2019","journal-title":"Physiol Rev"},{"key":"10.1016\/j.autrev.2024.103532_bb0435","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/JIR.S284941","article-title":"Studying neutrophil function in vitro: cell models and environmental factors","volume":"14","author":"Blanter","year":"2021","journal-title":"J Inflamm"},{"key":"10.1016\/j.autrev.2024.103532_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.649693","article-title":"Neutrophils in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus: same foe different M.O","volume":"12","author":"Fresneda Alarcon","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103532_bb0445","first-page":"402","article-title":"The emerging role of neutrophils in autoimmune-associated disorders: effector, predictor, and therapeutic targets","volume":"2021","author":"Fu","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.autrev.2024.103532_bb0450","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.3389\/fimmu.2019.02734","article-title":"Neutrophils\u2014important communicators in systemic lupus erythematosus and antiphospholipid syndrome","volume":"10","author":"Wirestam","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103532_bb0455","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood.V86.9.3553.bloodjournal8693553","article-title":"Heterogeneity of neutrophil antibodies in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"86","author":"Lamour","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103532_bb0460","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jneuroim.2006.05.026","article-title":"Upregulation of myeloperoxidase in patients with opticospinal multiple sclerosis: positive correlation with disease severity","volume":"178","author":"Minohara","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2024.103532_bb0465","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jneuroim.2011.11.009","article-title":"Neutrophils in multiple sclerosis are characterized by a primed phenotype","volume":"242","author":"Naegele","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2024.103532_bb0470","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1084\/jem.20141015","article-title":"Neutrophil-related factors as biomarkers in EAE and MS","volume":"212","author":"Rumble","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2024.103532_bb0475","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.1202613","article-title":"Neutrophils amplify autoimmune central nervous system infiltrates by maturing local APCs","volume":"191","author":"Steinbach","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2024.103532_bb0480","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.4049\/jimmunol.1400401","article-title":"Neutrophils mediate blood\u2013spinal cord barrier disruption in demyelinating neuroinflammatory diseases","volume":"193","author":"Aub\u00e9","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2024.103532_bb0485","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.imbio.2007.07.001","article-title":"Role of different protein tyrosine kinases in fMLP-induced neutrophil transmigration","volume":"213","author":"Zen","year":"2008","journal-title":"Immunobiology"},{"key":"10.1016\/j.autrev.2024.103532_bb0490","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.4049\/jimmunol.170.10.5235","article-title":"Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor","volume":"170","author":"Gilbert","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2024.103532_bb0495","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1189\/jlb.0804479","article-title":"Signaling through CD16b in human neutrophils involves the Tec family of tyrosine kinases","volume":"78","author":"Fernandes","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.autrev.2024.103532_bb0500","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1080\/10428194.2020.1753043","article-title":"The effect of ibrutinib on neutrophil and \u03b3\u03b4 T cell functions","volume":"61","author":"Risnik","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.autrev.2024.103532_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109469","article-title":"Ibrutinib suppresses the activation of neutrophils and macrophages and exerts therapeutic effect on acute peritonitis induced by zymosan","volume":"113","author":"Guo","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2024.103532_bb0510","doi-asserted-by":"crossref","first-page":"350","DOI":"10.5115\/acb.20.299","article-title":"Ibrutinib reduces neutrophil infiltration, preserves neural tissue and enhances locomotor recovery in mouse contusion model of spinal cord injury","volume":"54","author":"Torabi","year":"2021","journal-title":"Anat Cell Biol"},{"key":"10.1016\/j.autrev.2024.103532_bb0515","first-page":"95","article-title":"Second generation BTK inhibitors impair the anti-fungal response of macrophages and neutrophils","author":"Colado","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2024.103532_bb0520","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103532_bb0525","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.autrev.2024.103532_bb0530","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s41467-019-09160-7","article-title":"Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia","volume":"10","author":"Perdomo","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2024.103532_bb0535","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/bloodadvances.2019000617","article-title":"Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (Fc\u03b3RIIA): a new option in HIT?","volume":"3","author":"Goldmann","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.autrev.2024.103532_bb0540","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103532_bb0545","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s12185-022-03514-6","article-title":"Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies","volume":"117","author":"Munakata","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.autrev.2024.103532_bb0550","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/ajh.27064","article-title":"Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: a phase 2, multicenter, open-label study","volume":"98","author":"Deng","year":"2023","journal-title":"Am J Hematol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T22:25:50Z","timestamp":1716243950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224000235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":111,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1568997224000235"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103532","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103532"}}